| |
| |
|
| Insider
Information: |
Kumar Neil |
| Relationship: |
Director |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
4,867,524 |
|
|
Indirect Shares
|
31,586,701 |
|
|
| Direct
Value |
$141,644,948 |
|
|
|
Indirect Value
|
$3,061,816,650 |
|
|
| Total
Shares |
36,454,225 |
|
|
| Total
Value |
$3,203,461,598 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 481.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eidos Therapeutics, Inc. |
EIDX |
Chief Executive Office... |
2018-06-22 |
0 |
2019-07-03 |
24,575,501 |
Premium* |
|
|
Bridgebio Pharma, Inc. |
BBIO |
|
2024-02-16 |
4,867,524 |
2024-02-16 |
2,008,408 |
Premium* |
|
|
Lianbio |
LIAN |
Director |
|
0 |
2021-10-29 |
5,002,792 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2024-02-16 |
4 |
D |
$37.21 |
$1,783,178 |
D/D |
(47,922) |
4,867,524 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2024-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
102,249 |
4,915,446 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-11-17 |
4 |
AS |
$29.10 |
$1,500,038 |
D/D |
(51,552) |
4,813,197 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-11-16 |
4 |
D |
$28.86 |
$1,463,115 |
D/D |
(50,697) |
4,864,749 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-11-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
102,249 |
4,915,446 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-08-17 |
4 |
AS |
$28.59 |
$1,473,784 |
D/D |
(51,552) |
4,813,197 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-08-16 |
4 |
D |
$29.80 |
$1,510,800 |
D/D |
(50,698) |
4,864,749 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-08-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
102,250 |
4,915,447 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-05-17 |
4 |
AS |
$14.01 |
$722,218 |
D/D |
(51,552) |
4,813,197 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-05-16 |
4 |
D |
$14.09 |
$714,321 |
D/D |
(50,697) |
4,864,749 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-05-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
102,249 |
4,915,446 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-05-03 |
4 |
AS |
$14.18 |
$1,701,744 |
I/I |
(120,000) |
1,012,722 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-04-05 |
4 |
AS |
$15.46 |
$1,855,656 |
I/I |
(120,000) |
1,132,722 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-03-03 |
4 |
AS |
$10.96 |
$1,315,224 |
I/I |
(120,000) |
1,252,722 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-02-17 |
4 |
AS |
$12.70 |
$569,073 |
D/D |
(44,798) |
4,813,197 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-02-16 |
4 |
D |
$12.64 |
$302,197 |
D/D |
(23,908) |
4,857,995 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
68,706 |
4,881,903 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2023-02-03 |
4 |
AS |
$11.01 |
$1,320,696 |
I/I |
(120,000) |
1,372,722 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2022-12-21 |
4 |
S |
$0.00 |
$0 |
I/I |
(200,000) |
995,686 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2022-11-17 |
4 |
S |
$9.40 |
$325,606 |
D/D |
(34,640) |
4,813,197 |
0 |
% |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2022-11-16 |
4 |
D |
$9.64 |
$328,396 |
D/D |
(34,066) |
4,847,837 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2022-11-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
68,706 |
4,881,903 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2022-08-16 |
4 |
D |
$11.08 |
$306,883 |
D/D |
(27,697) |
4,813,197 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2022-08-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
68,705 |
4,840,894 |
0 |
- |
|
| BBIO |
Bridgebio Pharma, Inc. |
CEO and President |
• • – |
2022-05-16 |
4 |
D |
$6.74 |
$160,136 |
D/D |
(23,759) |
4,772,189 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
